PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis
Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/2/133 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588680297971712 |
|---|---|
| author | Patrícia Marques-Alves Lino Gonçalves Maria João Ferreira |
| author_facet | Patrícia Marques-Alves Lino Gonçalves Maria João Ferreira |
| author_sort | Patrícia Marques-Alves |
| collection | DOAJ |
| description | Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeoxyglucose (FDG) uptake, can reveal microvascular dysfunction, ischemia, and increased metabolic demands in the hypertrophied myocardium. These abnormalities are linked to several factors influencing disease progression, including arrhythmia development, ventricular dilation, and myocardial fibrosis. Fibroblast activation can also be evaluated using PET imaging, providing further insights into early-stage myocardial fibrosis. Conflicting findings underscore the need for further research into PET’s role in risk stratification for HCM. If PET can establish a connection between parameters such as abnormal MBF or increased FDG uptake and SCD risk, it could enhance predictive accuracy. Additionally, PET holds significant potential for monitoring therapeutic outcomes. The aim of this review is to provide a comprehensive overview of the most significant data on disease progression, risk stratification, and prognosis in patients with HCM using cardiac PET-CT imaging. |
| format | Article |
| id | doaj-art-28178fea0c7d41fbb2270ca07d814bb2 |
| institution | Kabale University |
| issn | 2075-4418 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj-art-28178fea0c7d41fbb2270ca07d814bb22025-01-24T13:28:51ZengMDPI AGDiagnostics2075-44182025-01-0115213310.3390/diagnostics15020133PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and PrognosisPatrícia Marques-Alves0Lino Gonçalves1Maria João Ferreira2Cardiology Department, Coimbra Hospital and University Center, 3004-561 Coimbra, PortugalCardiology Department, Coimbra Hospital and University Center, 3004-561 Coimbra, PortugalCardiology Department, Coimbra Hospital and University Center, 3004-561 Coimbra, PortugalHypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeoxyglucose (FDG) uptake, can reveal microvascular dysfunction, ischemia, and increased metabolic demands in the hypertrophied myocardium. These abnormalities are linked to several factors influencing disease progression, including arrhythmia development, ventricular dilation, and myocardial fibrosis. Fibroblast activation can also be evaluated using PET imaging, providing further insights into early-stage myocardial fibrosis. Conflicting findings underscore the need for further research into PET’s role in risk stratification for HCM. If PET can establish a connection between parameters such as abnormal MBF or increased FDG uptake and SCD risk, it could enhance predictive accuracy. Additionally, PET holds significant potential for monitoring therapeutic outcomes. The aim of this review is to provide a comprehensive overview of the most significant data on disease progression, risk stratification, and prognosis in patients with HCM using cardiac PET-CT imaging.https://www.mdpi.com/2075-4418/15/2/133hypertrophic cardiomyopathyPET-CT imagingsudden cardiac death |
| spellingShingle | Patrícia Marques-Alves Lino Gonçalves Maria João Ferreira PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis Diagnostics hypertrophic cardiomyopathy PET-CT imaging sudden cardiac death |
| title | PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis |
| title_full | PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis |
| title_fullStr | PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis |
| title_full_unstemmed | PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis |
| title_short | PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis |
| title_sort | pet ct imaging in hypertrophic cardiomyopathy a narrative review on risk stratification and prognosis |
| topic | hypertrophic cardiomyopathy PET-CT imaging sudden cardiac death |
| url | https://www.mdpi.com/2075-4418/15/2/133 |
| work_keys_str_mv | AT patriciamarquesalves petctimaginginhypertrophiccardiomyopathyanarrativereviewonriskstratificationandprognosis AT linogoncalves petctimaginginhypertrophiccardiomyopathyanarrativereviewonriskstratificationandprognosis AT mariajoaoferreira petctimaginginhypertrophiccardiomyopathyanarrativereviewonriskstratificationandprognosis |